Transcranial magnetic stimulator MagXite

Unprecedented early Amyotrophic lateral sclerosis (ALS) detection. Accurate evaluation of drug efficacy. Enhanced differentiation of ALS from non- ALS disorders. A new era in ALS Diagnostics with MagXite Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and universally fatal neurodegenerative disorder of motor neurons in the spinal cord, brainstem and motor cortex. There is currently no cure for ALS. Early and precise ALS detection is paramount. In ALS, short-interval intracortical inhibition (SICI) is reduced and intracortical facilitation (ICF) is increased, signifying cortical hyperexcitability. MagXite is powered by diagnostic technology developed by Professor Steve Vucic and Professor Matthew Kiernan. The underlying software evolved through their pioneering studies in thousands of patients with neurological diseases including stroke, multiple sclerosis Parkinson’s disease, movement disorders, migraine and epilepsy. Most critically, our MagXite protocols have been refined for ALS, where the technique has developed as a potential diagnostic biomarker, as well as a monitor of therapeutic efficacy for FDA approved medications including riluzole, and the discovery of novel therapeutics, with clinical trials underway worldwide. Unlock the future with MagXite Unprecedented Early ALS Detection The threshold tracking technique hastens the diagnosis of ALS by 8.3 months when compared to EL-Escorial criteria.* Enhanced Precision The threshold tracking technique differentiated ALS from non-ALS disorders with a sensitivity of 74% and specificity of 81% at an early stage in the disease.**